Ethris GmbH is a Germany-based biotechnology company developing RNA-based therapeutics and vaccines, with a core focus on the design, chemical modification, and formulation of messenger RNA (mRNA) and other nucleic acids. Headquartered in Planegg near Munich, the company advances drug candidates for respiratory and other diseases, emphasizing clinically viable delivery and dosing strategies.
Ethris’ work spans sequence engineering, analytical characterization, and drug product development for nucleic acid medicines. The company develops non-viral delivery systems—such as lipid nanoparticle (LNP) formulations and inhaled/aerosolizable dosage forms—to enable targeted, local or systemic administration. Ethris collaborates with pharmaceutical manufacturers, materials suppliers, and CDMOs to translate nucleic acid technologies from preclinical research into early clinical development, contributing know-how in formulation science, stability, and scalable process development relevant to the chemical and life-science supply chain.
Funding will advance ETH47 into Phase 2b for asthma and COPD and support ETH52/ETH53 mucosal influenza and pandemic preparedness programmes.
The EU funds next-gen flu vaccines to enhance protection, speed up development, and improve pandemic readiness through pre-commercial procurement.
The partnership aims to enhance nucleic acid delivery with a novel lipid nanoparticle platform, improving stability and targeting for therapies and vaccines.
